Stacey A Cohen1, Emily H Turner2, Mallory B Beightol2, Angela Jacobson2, Ted A Gooley3, Stephen J Salipante2, Sigurdis Haraldsdottir4, Christina Smith2, Sheena Scroggins2, Jonathan F Tait2, William M Grady5, Edward H Lin1, David E Cohn6, Paul J Goodfellow6, Mark W Arnold7, Albert de la Chapelle8, Rachel Pearlman9, Heather Hampel9, Colin C Pritchard10. 1. Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington; Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington. 2. Department of Laboratory Medicine, University of Washington, Seattle, Washington. 3. Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington. 4. Division of Medical Oncology, Department of Medicine, Stanford University, Stanford, California. 5. Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, Washington; Division of Gastroenterology, University of Washington, Seattle, Washington. 6. Division of Gynecologic Oncology, The Ohio State University, Columbus, Ohio. 7. Department of Surgery, The Ohio State University College of Medicine, Columbus, Ohio. 8. Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, Ohio. 9. Division of Human Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. 10. Department of Laboratory Medicine, University of Washington, Seattle, Washington. Electronic address: cpritch@uw.edu.
Abstract
BACKGROUND & AIMS: Some colorectal and endometrial tumors with microsatellite instability not attributable to MLH1 hypermethylation or germline mutations contain 2 or more somatic mutations in genes encoding mismatch repair (MMR) proteins. We sought to define the molecular phenotype of this newly recognized tumor subtype. METHODS: From 2 prospective studies of the efficacy of screening for Lynch syndrome, we identified patients with colorectal and endometrial tumors who had 2 or more somatic (but not germline) mutations in genes encoding MMR proteins (double somatic). We determined the frequencies of tumor mutations in PIK3CA, BRAF, KRAS, NRAS, and PTEN by targeted next-generation sequencing and used logistic-regression models to compare them with those from patients with Lynch syndrome, MLH1-hypermethylated, or microsatellite-stable tumors. We validated our findings using independent data sets from The Cancer Genome Atlas. RESULTS: Among colorectal cancer cases, we found that 14 of 21 (67%) patients with double somatic tumors also had PIK3CA mutations, compared with 4 of 18 (22%) tumors from patients with Lynch syndrome, 2 of 10 (20%) tumors with MLH1 hypermethylation, and 12 of 78 (15%) tumors with microsatellite stability (P < .0001 for patients with double somatic tumors vs other subgroups). Mutations in PIK3CA were detected in all 13 patients with double somatic endometrial cancers (P = .04 compared with other subgroups). We did not detect BRAF mutations in patients with double somatic colorectal tumors or Lynch syndrome. We found highly similar results in a validation cohort from The Cancer Genome Atlas (113 patients with colorectal tumors, 178 endometrial tumors); 100% of double somatic cases had a somatic mutation in PIK3CA (P < .0001 compared with other subgroups). CONCLUSIONS: Most patients with colorectal or endometrial tumors with 2 or more somatic (but not germline) mutations in MMR proteins also have mutations in PIK3CA; mutations in PIK3CA are detected at substantially higher frequencies in these double somatic tumors than in other microsatellite-instability subgroups. PIK3CA mutation status might be used to identify a specific group of colorectal tumors, and to select treatment or determine prognosis.
BACKGROUND & AIMS: Some colorectal and endometrial tumors with microsatellite instability not attributable to MLH1 hypermethylation or germline mutations contain 2 or more somatic mutations in genes encoding mismatch repair (MMR) proteins. We sought to define the molecular phenotype of this newly recognized tumor subtype. METHODS: From 2 prospective studies of the efficacy of screening for Lynch syndrome, we identified patients with colorectal and endometrial tumors who had 2 or more somatic (but not germline) mutations in genes encoding MMR proteins (double somatic). We determined the frequencies of tumor mutations in PIK3CA, BRAF, KRAS, NRAS, and PTEN by targeted next-generation sequencing and used logistic-regression models to compare them with those from patients with Lynch syndrome, MLH1-hypermethylated, or microsatellite-stable tumors. We validated our findings using independent data sets from The Cancer Genome Atlas. RESULTS: Among colorectal cancer cases, we found that 14 of 21 (67%) patients with double somatic tumors also had PIK3CA mutations, compared with 4 of 18 (22%) tumors from patients with Lynch syndrome, 2 of 10 (20%) tumors with MLH1 hypermethylation, and 12 of 78 (15%) tumors with microsatellite stability (P < .0001 for patients with double somatic tumors vs other subgroups). Mutations in PIK3CA were detected in all 13 patients with double somatic endometrial cancers (P = .04 compared with other subgroups). We did not detect BRAF mutations in patients with double somatic colorectal tumors or Lynch syndrome. We found highly similar results in a validation cohort from The Cancer Genome Atlas (113 patients with colorectal tumors, 178 endometrial tumors); 100% of double somatic cases had a somatic mutation in PIK3CA (P < .0001 compared with other subgroups). CONCLUSIONS: Most patients with colorectal or endometrialtumors with 2 or more somatic (but not germline) mutations in MMR proteins also have mutations in PIK3CA; mutations in PIK3CA are detected at substantially higher frequencies in these double somatic tumors than in other microsatellite-instability subgroups. PIK3CA mutation status might be used to identify a specific group of colorectal tumors, and to select treatment or determine prognosis.
Authors: Jordi Rodon; Irene Braña; Lillian L Siu; Maja J De Jonge; Natasha Homji; David Mills; Emmanuelle Di Tomaso; Celine Sarr; Lucia Trandafir; Cristian Massacesi; Ferry Eskens; Johanna C Bendell Journal: Invest New Drugs Date: 2014-03-21 Impact factor: 3.850
Authors: Michael Kloth; Vanessa Ruesseler; Christoph Engel; Katharina Koenig; Martin Peifer; Erika Mariotti; Helen Kuenstlinger; Alexandra Florin; Ursula Rommerscheidt-Fuss; Ulrike Koitzsch; Claudia Wodtke; Frank Ueckeroth; Stefanie Holzapfel; Stefan Aretz; Peter Propping; Markus Loeffler; Sabine Merkelbach-Bruse; Margarete Odenthal; Nicolaus Friedrichs; Lukas Carl Heukamp; Thomas Zander; Reinhard Buettner Journal: Gut Date: 2015-04-28 Impact factor: 23.059
Authors: Meghan L Rudd; Jessica C Price; Sarah Fogoros; Andrew K Godwin; Dennis C Sgroi; Maria J Merino; Daphne W Bell Journal: Clin Cancer Res Date: 2011-01-25 Impact factor: 12.531
Authors: Prasanth Ganesan; Filip Janku; Aung Naing; David S Hong; Apostolia M Tsimberidou; Gerald S Falchook; Jennifer J Wheler; Sarina A Piha-Paul; Siqing Fu; Vanda M Stepanek; J Jack Lee; Rajyalakshmi Luthra; Michael J Overman; E Scott Kopetz; Robert A Wolff; Razelle Kurzrock Journal: Mol Cancer Ther Date: 2013-10-03 Impact factor: 6.261
Authors: Eduardo Vilar; Bhramar Mukherjee; Rork Kuick; Leon Raskin; David E Misek; Jeremy M G Taylor; Thomas J Giordano; Samir M Hanash; Eric R Fearon; Gad Rennert; Stephen B Gruber Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: María Rodríguez-Soler; Lucía Pérez-Carbonell; Carla Guarinos; Pedro Zapater; Adela Castillejo; Victor M Barberá; Miriam Juárez; Xavier Bessa; Rosa M Xicola; Juan Clofent; Luis Bujanda; Francesc Balaguer; Josep-Maria Reñé; Luisa de-Castro; José C Marín-Gabriel; Angel Lanas; Joaquín Cubiella; David Nicolás-Pérez; Alejandro Brea-Fernández; Sergi Castellví-Bel; Cristina Alenda; Clara Ruiz-Ponte; Angel Carracedo; Antoni Castells; Montserrat Andreu; Xavier Llor; José L Soto; Artemio Payá; Rodrigo Jover Journal: Gastroenterology Date: 2013-01-24 Impact factor: 22.682
Authors: Sigurdis Haraldsdottir; Heather Hampel; Jerneja Tomsic; Wendy L Frankel; Rachel Pearlman; Albert de la Chapelle; Colin C Pritchard Journal: Gastroenterology Date: 2014-09-03 Impact factor: 22.682
Authors: Heather Hampel; Rachel Pearlman; Mallory Beightol; Weiqiang Zhao; Daniel Jones; Wendy L Frankel; Paul J Goodfellow; Ahmet Yilmaz; Kristin Miller; Jason Bacher; Angela Jacobson; Electra Paskett; Peter G Shields; Richard M Goldberg; Albert de la Chapelle; Brian H Shirts; Colin C Pritchard Journal: JAMA Oncol Date: 2018-06-01 Impact factor: 31.777
Authors: Liana B Guedes; Emmanuel S Antonarakis; Michael T Schweizer; Nooshin Mirkheshti; Fawaz Almutairi; Jong Chul Park; Stephanie Glavaris; Jessica Hicks; Mario A Eisenberger; Angelo M De Marzo; Jonathan I Epstein; William B Isaacs; James R Eshleman; Colin C Pritchard; Tamara L Lotan Journal: Clin Cancer Res Date: 2017-08-08 Impact factor: 12.531
Authors: Piotr Olcha; Anna Winiarska-Mieczan; Małgorzata Kwiecień; Łukasz Nowakowski; Andrzej Miturski; Andrzej Semczuk; Bożena Kiczorowska; Krzysztof Gałczyński Journal: Int J Mol Sci Date: 2022-06-16 Impact factor: 6.208
Authors: Alicia Latham; Preethi Srinivasan; Yelena Kemel; Jinru Shia; Chaitanya Bandlamudi; Diana Mandelker; Sumit Middha; Jaclyn Hechtman; Ahmet Zehir; Marianne Dubard-Gault; Christina Tran; Carolyn Stewart; Margaret Sheehan; Alexander Penson; Deborah DeLair; Rona Yaeger; Joseph Vijai; Semanti Mukherjee; Jesse Galle; Mark A Dickson; Yelena Janjigian; Eileen M O'Reilly; Neil Segal; Leonard B Saltz; Diane Reidy-Lagunes; Anna M Varghese; Dean Bajorin; Maria I Carlo; Karen Cadoo; Michael F Walsh; Martin Weiser; Julio Garcia Aguilar; David S Klimstra; Luis A Diaz; Jose Baselga; Liying Zhang; Marc Ladanyi; David M Hyman; David B Solit; Mark E Robson; Barry S Taylor; Kenneth Offit; Michael F Berger; Zsofia K Stadler Journal: J Clin Oncol Date: 2018-10-30 Impact factor: 50.717